173 related articles for article (PubMed ID: 38139437)
1. Therapeutic Potential of Regorafenib in Cisplatin-Resistant Bladder Cancer with High Epithelial-Mesenchymal Transition and Stemness Properties.
Kuan FC; Li JM; Huang YC; Chang SF; Shi CS
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139437
[TBL] [Abstract][Full Text] [Related]
2. Cordycepin Resensitizes T24R2 Cisplatin-Resistant Human Bladder Cancer Cells to Cisplatin by Inactivating Ets-1 Dependent MDR1 Transcription.
Oh SS; Lee KW; Madhi H; Jeong JW; Park S; Kim M; Lee Y; Han HT; Hwangbo C; Yoo J; Kim KD
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32131547
[TBL] [Abstract][Full Text] [Related]
3. Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines.
Kim SH; Ho JN; Jin H; Lee SC; Lee SE; Hong SK; Lee JW; Lee ES; Byun SS
Investig Clin Urol; 2016 Jan; 57(1):63-72. PubMed ID: 26966728
[TBL] [Abstract][Full Text] [Related]
4. Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder cancer cell lines.
Hong JH; Lee E; Hong J; Shin YJ; Ahn H
BJU Int; 2002 Jul; 90(1):113-7. PubMed ID: 12081782
[TBL] [Abstract][Full Text] [Related]
5. PRDX2 regulates stemness contributing to cisplatin resistance and metastasis in bladder cancer.
Li P; Wang W; Zhu B; Wang Y; Li J; Wang C; Wang C; Li Q
Environ Toxicol; 2024 May; 39(5):2869-2880. PubMed ID: 38294069
[TBL] [Abstract][Full Text] [Related]
6. Synergistic Antitumor Effects of Combined Treatment with HSP90 Inhibitor and PI3K/mTOR Dual Inhibitor in Cisplatin-Resistant Human Bladder Cancer Cells.
Kim HJ; Gong MK; Yoon CY; Kang J; Yun M; Cho NH; Rha SY; Choi YD
Yonsei Med J; 2020 Jul; 61(7):587-596. PubMed ID: 32608202
[TBL] [Abstract][Full Text] [Related]
7. Ultrastructural change due to acquired cisplatin resistance in human bladder cancer cells.
Yoon SJ; Park I; Kwak C; Lee E
Oncol Rep; 2003; 10(5):1363-7. PubMed ID: 12883708
[TBL] [Abstract][Full Text] [Related]
8. The role of c-FLIP in cisplatin resistance of human bladder cancer cells.
Lee S; Yoon CY; Byun SS; Lee E; Lee SE
J Urol; 2013 Jun; 189(6):2327-34. PubMed ID: 23313194
[TBL] [Abstract][Full Text] [Related]
9. Suberoylanilide Hydroxamic Acid Can Re-sensitize a Cisplatin-Resistant Human Bladder Cancer.
Ryu H; Jin H; Ho JN; Bae J; Lee E; Lee SE; Lee S
Biol Pharm Bull; 2019; 42(1):66-72. PubMed ID: 30606990
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic effects of kazinol A derived from Broussonetia papyrifera on human bladder cancer cells, T24 and T24R2.
Park S; Fudhaili A; Oh SS; Lee KW; Madhi H; Kim DH; Yoo J; Ryu HW; Park KH; Kim KD
Phytomedicine; 2016 Nov; 23(12):1462-1468. PubMed ID: 27765366
[TBL] [Abstract][Full Text] [Related]
11. Effects of Concurrent Chemoradiotherapy on the Metastasis and the Mesenchymal Transition of Bladder Urothelial Carcinoma Cells.
Pan Y; Hong YC; Hsiao CH; Shih HJ; Huang SH; Wu SC; Chang CP; Chiu SC; Cho DY; Shih PH
Anticancer Res; 2021 Oct; 41(10):4957-4968. PubMed ID: 34593443
[TBL] [Abstract][Full Text] [Related]
12. Sensitization of cisplatin resistant bladder tumor by combination of cisplatin treatment and co-culture of dendritic cells with apoptotic bladder cancer cells.
Zhang Q; Chen Z
Cell Mol Biol (Noisy-le-grand); 2018 Jul; 64(10):102-107. PubMed ID: 30084800
[TBL] [Abstract][Full Text] [Related]
13. Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression.
Daga M; Pizzimenti S; Dianzani C; Cucci MA; Cavalli R; Grattarola M; Ferrara B; Scariot V; Trotta F; Barrera G
Phytomedicine; 2019 Mar; 56():156-164. PubMed ID: 30668336
[TBL] [Abstract][Full Text] [Related]
14. VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cells.
Li Y; Yang X; Su LJ; Flaig TW
Oncol Rep; 2010 Oct; 24(4):1019-28. PubMed ID: 20811684
[TBL] [Abstract][Full Text] [Related]
15. Trifluoperazine, an Antipsychotic Drug, Effectively Reduces Drug Resistance in Cisplatin-Resistant Urothelial Carcinoma Cells via Suppressing Bcl-xL: An In Vitro and In Vivo Study.
Kuo KL; Liu SH; Lin WC; Hsu FS; Chow PM; Chang YW; Yang SP; Shi CS; Hsu CH; Liao SM; Chang HC; Huang KH
Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31262032
[TBL] [Abstract][Full Text] [Related]
16. Up-regulation of Bfl-1/A1 via NF-kappaB activation in cisplatin-resistant human bladder cancer cell line.
Kim JK; Kim KD; Lee E; Lim JS; Cho HJ; Yoon HK; Cho MY; Baek KE; Park YP; Paik SG; Choe YK; Lee HG
Cancer Lett; 2004 Aug; 212(1):61-70. PubMed ID: 15246562
[TBL] [Abstract][Full Text] [Related]
17. SOX8 regulates cancer stem-like properties and cisplatin-induced EMT in tongue squamous cell carcinoma by acting on the Wnt/β-catenin pathway.
Xie SL; Fan S; Zhang SY; Chen WX; Li QX; Pan GK; Zhang HQ; Wang WW; Weng B; Zhang Z; Li JS; Lin ZY
Int J Cancer; 2018 Mar; 142(6):1252-1265. PubMed ID: 29071717
[TBL] [Abstract][Full Text] [Related]
18. Cancer stem-like cells contribute to cisplatin resistance and progression in bladder cancer.
Zhang Y; Wang Z; Yu J; Shi Jz; Wang C; Fu Wh; Chen Zw; Yang J
Cancer Lett; 2012 Sep; 322(1):70-7. PubMed ID: 22343321
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effects of MutT homolog 1 inhibitors in human bladder cancer cells.
Lee JW; Lee S; Ho JN; Youn JI; Byun SS; Lee E
Biosci Biotechnol Biochem; 2019 Dec; 83(12):2265-2271. PubMed ID: 31362565
[TBL] [Abstract][Full Text] [Related]
20. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
Liu J; Chen X; Ward T; Pegram M; Shen K
Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
